Pacira Publishes Study Of EXPAREL As Sciatic Nerve Block in Popliteal Fossa For Patients After Bunionectomy
Portfolio Pulse from Benzinga Newsdesk
Pacira Biosciences published a study showing that EXPAREL, when used as a sciatic nerve block in the popliteal fossa for patients after bunionectomy, significantly reduces pain and opioid consumption through 96 hours compared to an active comparator. The study also found a significantly greater proportion of patients receiving EXPAREL were opioid-free.
February 15, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pacira Biosciences' study on EXPAREL demonstrates its effectiveness in reducing pain and opioid consumption post-bunionectomy, potentially boosting its market appeal and usage.
The positive results from the study directly relate to Pacira Biosciences' product, EXPAREL, highlighting its effectiveness and potential to reduce opioid dependency in post-surgical pain management. This could lead to increased demand and usage of EXPAREL, positively impacting Pacira's revenues and market position in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100